Aurinia Pharmaceuticals Inc. (AUPH)

Over the past six months, Aurinia Pharmaceuticals' stock price has experienced notable events. As of January 7, 2026, the share price was $16.03, representing a significant increase of 92.21% from $8.34 on January 8, 2025. The company reported strong financial results for Q3 2025 on November 4, 2025, with total revenue increasing by 8% to $73.5 million and net product sales of LUPKYNIS growing by 27% year-over-year. In October 2025, Roche's Gazyva received FDA approval for lupus nephritis, introducing a new competitor to the market. In November 2025, Aurinia responded to an FDA information request regarding Lupkynis, which included new analyses demonstrating the drug's benefits beyond complete renal response rates. This period also saw controversy surrounding a former FDA official who made critical comments about voclosporin on LinkedIn, leading to a lawsuit filed by Aurinia.

Analysis of Aurinia Pharmaceuticals Inc. seasonal charts suggests a potential seasonal pattern in its stock performance. A "Buy Date" of November 23 and a "Sell Date" of March 22 has historically resulted in a geometric average return of 26.82% above the S&P 500 Total Return Index over the past 12 years. This indicates a period of seasonal strength for the stock. However, this specific seasonal timeframe correlates poorly with the broader Healthcare sector's period of seasonal strength, which typically runs from April 25 to December 4. The company's product, LUPKYNIS, addresses a chronic autoimmune condition, lupus nephritis, which typically does not exhibit strong seasonal demand fluctuations.

Aurinia Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases with unmet medical needs. The company's flagship product is LUPKYNIS, an oral therapy approved for treating adult patients with active lupus nephritis. Aurinia is also advancing AUR200 for potential treatment of other autoimmune diseases.

Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia, Canada, and maintains a presence across North America. The company has research and development facilities in both Canada and the United States, with the majority of its revenue generated from the United States. Aurinia has a collaboration with Otsuka Pharmaceutical Co., Ltd., for marketing and selling LUPKYNIS in Japan.

In the past year, Aurinia Pharmaceuticals' brand reputation was notably impacted by a controversy involving a former FDA official, Dr. George Tidmarsh. In September 2025, Tidmarsh posted critical comments on LinkedIn regarding voclosporin, stating that it had "significant toxicity" and had not been shown to provide a "direct clinical benefit" for patients. Aurinia Pharmaceuticals responded by filing a lawsuit against Tidmarsh and publicly affirmed its confidence in the "favorable benefit/risk profile" of Lupkynis. The company also responded to an FDA information request on Lupkynis with new analyses supporting its benefits.

Aurinia Pharmaceuticals Inc. has a diverse ownership structure. Institutional investors hold a significant portion of the company's stock, with approximately 50% ownership. According to TipRanks data, institutional investors hold about 17.09% of the stock, while insiders hold 11.42%, and retail investors hold 59.85%. Major institutional owners include Tang Capital Management Llc, BlackRock, Inc., NEA Management Company, LLC, Arrowstreet Capital, Limited Partnership, iShares Russell 2000 ETF (IWM), State Street Corp, Morgan Stanley, Vanguard Group Inc, Geode Capital Management, Llc, and Marshall Wace, Llp. Tang Capital Management, LLC is the largest shareholder, holding 8.6% of the company.